200
Participants
Start Date
May 31, 2004
Primary Completion Date
February 28, 2006
Study Completion Date
February 28, 2006
Atazanavir+ritonavir
Capsules, Oral, 300mg/100mg, once daily, 24 weeks.
Lopinavir+ritonavir
Capsules, Oral, 800mg/200mg, twice daily, 24 weeks.
Local Institution, Hobson City
Local Institution, Montgomery
Local Institution, Phoenix
Local Institution, Little Rock
Local Institution, Bakersfield
Local Institution, Los Angeles
Local Institution, San Francisco
Local Institution, San Mateo
Local Institution, Tarzana
Local Institution, West Hollywood
Local Institution, Norwalk
Local Institution, Washington D.C.
Local Institution, Atlantis
Local Institution, Fort Lauderdale
Local Institution, Jacksonville
Local Institution, Miami
Local Institution, Miami Beach
Local Institution, North Miami
Local Institution, Orlando
Local Institution, Plantation
Local Institution, Safety Harbor
Local Institution, Tampa
Local Institution, Atlanta
Local Institution, Decatur
Local Institution, Chicago
Local Institution, Indianapolis
Local Institution, Louisville
Local Institution, New Orleans
Local Institution, Boston
Local Institution, Springfield
Local Institution, Berkley
Local Institution, Jackson
Local Institution, St Louis
Local Institution, Las Vegas
Local Institution, East Orange
Local Institution, Hillsborough
Local Institution, Jersey City
Local Institution, Brooklyn
Local Institution, Mount Vernon
Local Institution, New York
Local Institution, Valhalla
Local Institution, Greenville
Local Institution, Huntersville
Local Institution, Winston-Salem
Local Institution, Oklahoma City
Local Institution, Philadelphia
Local Institution, Columbia
Local Institution, Dallas
Local Institution, Galveston
Local Institution, Harlingen
Local Institution, Houston
Local Institution, Hampton
Local Institution, Santruce
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY